Psoriatic Arthritis | NEJM Skip to main content NEJM Group Follow Us Facebook Twitter
Instagram YouTube LinkedIn Prepare to become a physician, build your knowledge, lead a …

Objective Adalimumab, a fully human, anti–tumor necrosis factor monoclonal antibody, was
evaluated for its safety and efficacy compared with placebo in the treatment of active …

… Kavanaugh and Ritchlin contributed equally to this work. … Ritchlin has received consulting
fees, speaking fees, and/ or … Ritchlin CT. Therapies for psoriatic enthesopathy: a systematic …

Background Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis
of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, …

Background Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory
disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human …

Psoriatic arthritis (PsA) is an inflammatory joint disease characterized by extensive bone
resorption. The mechanisms underlying this matrix loss have not been elucidated. We report …

Objective: To develop comprehensive recommendations for the treatment of the various
clinical manifestations of psoriatic arthritis (PsA) based on evidence obtained from a systematic …

Objective: To develop an evidence-based guideline for the pharmacologic and nonpharmacologic
treatment of psoriatic arthritis (PsA), as a collaboration between the American College …

Objective Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week
60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/…

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in
2012, but the evidence for these recommendations was only of indirect nature. These …